Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $23 from $21 and keeps a Perform rating on the shares. The firm maintains a balanced view on Acadia into 2026 following discussions with management and investors on several key recent updates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: U.S. Commercial Execution and Pipeline Optionality Drive Undervalued Buy Thesis Despite EU Trofinetide Delay
- Acadia Pharmaceuticals price target lowered to $31 from $35 at RBC Capital
- Closing Bell Movers: Palantir rallies 6% after Q4 beat
- Acadia Pharmaceuticals announces negative CHMP trend vole in Rett Syndrome
- Acadia Pharmaceuticals price target raised to $31 from $27 at BofA